Anti-diabetic drug use and reduced risk of Parkinson's disease: A community-based cohort study.
抗糖尿病藥物使用與帕金森病風險降低:一項社區基礎的隊列研究。
Parkinsonism Relat Disord 2024-09-11
Do oral antidiabetic medications alter the risk of Parkinson's disease? An updated systematic review and meta-analysis.
口服抗糖尿病藥物是否改變帕金森氏症的風險?一項更新的系統性回顧和荟萃分析。
Neurol Sci 2023-11-22
Meta-analysis of Association between Newer Glucose-Lowering Drugs and Risk of Parkinson's Disease.
新型降糖藥物與帕金森氏症風險之間的關聯的荟萃分析。
Mov Disord Clin Pract 2024-02-10
Use of dipeptidyl peptidase-4 inhibitors was associated with a lower risk of Parkinson's disease in diabetic patients.
糖尿病患者使用二肽基胜肽酶-4抑制劑與帕金森病風險降低相關。
Sci Rep 2023-12-28
DPP-4 inhibitors sitagliptin and PF-00734,200 mitigate dopaminergic neurodegeneration, neuroinflammation and behavioral impairment in the rat 6-OHDA model of Parkinson's disease.
DPP-4 抑制劑 sitagliptin 和 PF-00734,200 在大鼠 6-OHDA 帕金森氏症模型中緩解多巴胺能神經退化、神經炎症和行為障礙。
Geroscience 2024-04-02
Association between SGLT2 Inhibitors and Risk of Dementia and Parkinson's Disease: A Meta-Analysis of 12 Randomized Controlled Trials.
SGLT2抑制劑與失智症和帕金森病風險之間的關聯:12項隨機對照試驗的荟萃分析。
Am J Med 2024-07-08
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.
GLP-1 受體激動劑與 2 型糖尿病患者帕金森病風險:一項基於人群的隊列研究。
Mov Disord 2024-08-27
Sodium-glucose cotransporter 2 inhibitors and the risk of Parkinson disease in real-world patients with type 2 diabetes.
鈉-葡萄糖共轉運蛋白 2 抑制劑與實際世界中 2 型糖尿病患者罹患帕金森病的風險。
Diabetes Obes Metab 2024-09-11
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes.
SGLT2 抑制劑使用與 2 型糖尿病患者罹患癡呆症和帕金森病的風險。
Neurology 2024-09-18